- New drug discovery platform
BlinkBio Inc. has developed a proprietary technology platform with the potential to revolutionize drug discovery. The novel platform allows the self-assembly of high-affinity drugs from smaller building blocks directly on the biomolecular target inside the cell. The company has successfully raised financing and achieved technical proof of concept. The five-year goal is to establish the BlinkBio platform as a new way to target the “undruggable” in many disease states of high unmet need.
BlinkBio Inc. works closely with the founding faculty scientist from Weill Cornell Medicine.